[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

NRT Smoking Cessation Aids - Japan

June 2010 | 47 pages | ID: N36D4DD191FEN
Euromonitor International Ltd

US$ 900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Ever since the Health Promotion Law was implemented in 2003, there has been rising concern of passive smoking prevention. This resulted in the increasing smoking ban in many places nationwide. The law also increased the health consciousness of consumers, leading to promotions to quit smoking. NRT smoking cessation aids’ growth was driven by this trend in recent years. This continued in 2009, and sales enjoyed growth with the introduction of new formats, such as NRT patches being switched to OTC...

Euromonitor International's NRT Smoking Cessation Aids Products in Japan report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage: NRT Gum, NRT Inhalators, NRT Lozenges, NRT Patches, Other NRT

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Executive Summary
Consumer Healthcare Increases, Albeit at Lower Rate
Revised Pharmaceutical Law Impacts Consumer Healthcare Dynamics
Domestic Players Continue To Dominate Consumer Healthcare
Revised Pharmaceutical Law Impacts Consumer Healthcare Channels
Slower Growth Expected for Forecast Period
Key Trends and Developments
Revised Pharmaceutical Law Causes Controversy
Targeting the Active Ageing Society
Staying Fit Remains Priority Among Consumers
Recycling To Increase Sales
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
Consumer Healthcare Registration and Classification
Self-medication/self-care and Preventative Medicine
Switches
Summary 1 Consumer Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
Summary 2 Research Sources
Daiichi Sankyo Healthcare Co Ltd
Strategic Direction
Key Facts
Summary 3 Daiichi Sankyo Healthcare Co Ltd: Key Facts
Summary 4 Daiichi Sankyo Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 5 Daiichi Sankyo Healthcare Co Ltd: Competitive Position 2009
Eisai Co Ltd
Strategic Direction
Key Facts
Summary 6 Eisai Co Ltd: Key Facts
Summary 7 Eisai Co Ltd: Operational Indicators
Production
Competitive Positioning
Summary 8 Eisai Co Ltd: Competitive Position 2009
Hisamitsu Pharmaceutical Co Inc
Strategic Direction
Key Facts
Summary 9 Hisamitsu Pharmaceutical Co Inc: Key Facts
Summary 10 Hisamitsu Pharmaceutical Co Inc: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 11 Hisamitsu Pharmaceutical Co Inc: Competitive Position 2009
Lion Corp
Strategic Direction
Key Facts
Summary 12 Lion Corp: Key Facts
Summary 13 Lion Corp: Operational Indicators
Production
Competitive Positioning
Summary 14 Lion Corp: Competitive Position 2009
Miki Corp
Strategic Direction
Key Facts
Summary 15 Miki Corp: Key Facts
Company Background
Production
Summary 16 Miki Corp: Production Statistics 2008
Competitive Positioning
Summary 17 Miki Corp: Competitive Position 2009
Rohto Pharmaceutical Co Ltd
Strategic Direction
Key Facts
Summary 18 Rohto Pharmaceutical Co Ltd: Key Facts
Summary 19 Rohto Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 20 Rohto Pharmaceutical Co Ltd: Competitive Position 2009
Sato Pharmaceutical Co Ltd
Strategic Direction
Key Facts
Summary 21 Sato Pharmaceutical Co Ltd: Key Facts
Company Background
Production
Competitive Positioning
Summary 22 Sato Pharmaceutical Co Ltd: Competitive Position 2009
Ssp Co Ltd
Strategic Direction
Key Facts
Summary 23 SSP Co Ltd: Key Facts
Summary 24 SSP Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 25 SSP Co Ltd: Competitive Position 2009
Taisho Pharmaceutical Co Ltd
Strategic Direction
Key Facts
Summary 26 Taisho Pharmaceutical Co Ltd: Key Facts
Summary 27 Taisho Pharmaceutical Co Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 28 Taisho Pharmaceutical Co Ltd: Competitive Position 2009
Takeda Chemical Industries Ltd
Strategic Direction
Key Facts
Summary 29 Takeda Chemical Industries Ltd: Key Facts
Summary 30 Takeda Chemical Industries Ltd: Operational Indicators
Company Background
Production
Competitive Positioning
Summary 31 Takeda Chemical Industries Ltd: Competitive Position 2009
Headlines
Trends
Switches
Competitive Landscape
Prospects
Sector Indicators
  Table 12 Number of Smokers by Gender 2004-2009
Category Data
  Table 13 Sales of Smoking Cessation Aids by Subsector: Value 2004-2009
  Table 14 Sales of Smoking Cessation Aids by Subsector: % Value Growth 2004-2009
  Table 15 NRT Gum Flavours: % Value Breakdown 2006-2009
  Table 16 Smoking Cessation Aids Company Shares by Value 2005-2009
  Table 17 Smoking Cessation Aids Brand Shares by Value 2006-2009
  Table 18 Forecast Sales of Smoking Cessation Aids by Subsector: Value 2009-2014
  Table 19 Forecast Sales of Smoking Cessation Aids by Subsector: % Value Growth 2009-2014


More Publications